Agonists like liraglutide protect against cardiac hypertrophy and fibrosis by activating the AMPK/mTOR/p70S6K pathway and ATP‐sensitive potassium channels [33, 34, 35]. The gene discussed is PRKAA2; the disease is cardiac hypertrophy.